Literature DB >> 24583233

Viewpoints on vessels and vanishing bones in Gorham-Stout disease.

Michael T Dellinger1, Nupur Garg2, Bjorn R Olsen3.   

Abstract

Gorham-Stout disease (GSD) is a rare disorder characterized by the proliferation of endothelial-lined vessels in bone and the progressive destruction of bone. Although Jackson described the first case of GSD in 1838, the clinical and histological features of GSD were not defined until Gorham and Stout published their report on massive osteolysis in 1955. In the years since Gorham and Stout's groundbreaking publication, more than 300 cases of GSD have been described in the literature. These reports have revealed that the progressive resorption of bone in GSD causes severe physical deformities, disabilities, and life-threatening complications. Unfortunately, the underlying cause of GSD remains unknown and, as a result, the therapeutic options for individuals with GSD are limited. Here we review the latest advances in GSD research and present strategies to address basic and clinical research questions related to GSD.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gorham–Stout disease; Lymphangiogenesis; Lymphangiomatosis; Osteolysis; Vanishing bone disease

Mesh:

Year:  2014        PMID: 24583233     DOI: 10.1016/j.bone.2014.02.011

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  50 in total

1.  18F-NaF and 18F-FDG PET/CT in Gorham-Stout Disease.

Authors:  Georgios Z Papadakis; Corina Millo; Ulas Bagci; Jenny Blau; Michael T Collins
Journal:  Clin Nucl Med       Date:  2016-11       Impact factor: 7.794

2.  Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.

Authors:  Mizuho Kittaka; Kotoe Mayahara; Tomoyuki Mukai; Tetsuya Yoshimoto; Teruhito Yoshitaka; Jeffrey P Gorski; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2017-11-02       Impact factor: 6.741

Review 3.  The Lymphatic Vasculature in the 21st Century: Novel Functional Roles in Homeostasis and Disease.

Authors:  Guillermo Oliver; Jonathan Kipnis; Gwendalyn J Randolph; Natasha L Harvey
Journal:  Cell       Date:  2020-07-23       Impact factor: 41.582

4.  MR imaging findings of vertebral involvement in Gorham-Stout disease, generalized lymphatic anomaly, and kaposiform lymphangiomatosis.

Authors:  Hiroki Kato; Michio Ozeki; Toshiyuki Fukao; Masayuki Matsuo
Journal:  Jpn J Radiol       Date:  2017-08-09       Impact factor: 2.374

5.  Lymphatic Endothelial Cells Produce M-CSF, Causing Massive Bone Loss in Mice.

Authors:  Wensheng Wang; Hua Wang; Xichao Zhou; Xing Li; Wen Sun; Michael Dellinger; Brendan F Boyce; Lianping Xing
Journal:  J Bone Miner Res       Date:  2017-01-31       Impact factor: 6.741

6.  Craniofacial CT findings of Gorham-Stout disease and generalized lymphatic anomaly.

Authors:  Hiroki Kato; Michio Ozeki; Toshiyuki Fukao; Masayuki Matsuo
Journal:  Neuroradiology       Date:  2016-04-28       Impact factor: 2.804

Review 7.  Cortical bone development, maintenance and porosity: genetic alterations in humans and mice influencing chondrocytes, osteoclasts, osteoblasts and osteocytes.

Authors:  Tsuyoshi Isojima; Natalie A Sims
Journal:  Cell Mol Life Sci       Date:  2021-07-01       Impact factor: 9.261

8.  Lymphatics in bone arise from pre-existing lymphatics.

Authors:  Marco Monroy; Anna L McCarter; Devon Hominick; Nina Cassidy; Michael T Dellinger
Journal:  Development       Date:  2020-04-20       Impact factor: 6.868

9.  Primary versus trauma-induced Gorham-Stout disease.

Authors:  N Tanoue; L Moedano; M Witte; M Montague; A Lukefahr; M Bernas
Journal:  Lymphology       Date:  2018       Impact factor: 1.286

10.  Gorham-Stout disease: radiological, histological, and clinical features of 12 cases and review of literature.

Authors:  Yi Liu; Ding-Rong Zhong; Pei-Ran Zhou; Fang Lv; Dou-Dou Ma; Wei-Bo Xia; Yan Jiang; Ou Wang; Xiao-Ping Xing; Mei Li
Journal:  Clin Rheumatol       Date:  2014-09-18       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.